Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: An 123I-IBZM-SPECT study

Psychopharmacology

Volumn 172, Issue 2, 2004, Pages 165-169

  Lomeña, Francisco ^a,c   Catafau, Ana M ^b   Parellada, Eduard ^a   Bernardo, Miquel ^a   Font, Mireia ^a   Gutiérrez, Fernando ^a   Pav́a, Javier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Antipsychotics; D; I IBZM; Receptors; Schizophrenia; SPECT; Up regulation

Indexed keywords

DOPAMINE 2 RECEPTOR; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE I 123; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; RECEPTOR DENSITY; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; COMPARATIVE STUDY; METABOLISM; METHODOLOGY; NONPARAMETRIC TEST; PHYSIOLOGY; PROTEIN BINDING; SCINTISCANNING;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; CORPUS STRIATUM; FEMALE; HUMANS; MALE; PROTEIN BINDING; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 1642350062     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1644-2     Document Type: Article

References (26)

1. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99:463-472
2. 123I-IBZM SPECT study. Psychiatr Res Neuroimaging 107:87-97
3. Carlsson A (1988) The current status of dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186
4. 2 receptors. Psychopharmacology 74:122-124
5. 11C]raclopride. Arch Gen Psychiatry 47:213-219
6. 2 recepor blockade. Schizophr Res Suppl 60:241
7. Guy W (1976) Early Clinical Drug Evaluation Unit (ECDEU). National Institute of Mental Health, Rockville, Md., publication 76, p 338.
8. 2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51:116-123
9. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
10. 2 receptors, and dopamine uptake sites in postmortem striatal speciments from schizophrenic patients. Biol Psychiatry 36:827-35
11. Kornhuber J, Schultz A, Wiltfang J, Meineke I, Gleiter CH, Zöchling R, Boissl KW, Leblhuber F, Riederer P (1999) Persistence of haloperidol in human brain tissue. Am J Psychiatry 156:885-890
12. Laruelle M (1998) Imaging dopamine transmission in schizophrenia - a review and meta-analysis. Q J Nucl Med 42:211-221
13. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451
14. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162-174
15. MacKay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Synder SH (1982) Increased brain dopamine receptors in schizophrenia. Arch Gen Psychiatry 39:991-997
16. Ng GY, O'Dowd BF, Lee SP, Chung HT, Brann MR, Seeman P, George SR (1996) Dopamine receptor dimmers and receptor blocking peptides. Biochem Biophys Res Commun 227:200-204
17. Overall JE, Gorham DR (1973) The brief psychiatric rating scale. In: Lyerly SB (ed) Handbook of psychiatric rating scales, 2nd edn. National Institute of Mental Health, Clinical Research Branch, Rockville, Md., pp 23-25
18. Peralta V, Cuesta JM (1994) Validation de la Escala de los Síndromes Positivo y negativo (PANSS). Actas Luso Esp Neurol Psiquiatr Cienc Afines 22:171-177
19. 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 164:16-26
20. 4 receptors elevated in schizophrenia. Nature 365:411-445
21. 2 receptors in human subjects with iodine 123-IBZM. J Nucl Med 33:1964-1971
22. Soares JC, Innis RB (1999) Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry 46:600-615
23. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N (1988) Neurotransmitters, receptors and neuropeptides in postmortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121-137
24. 11C-N-methylsiperone. Psychiatry Res 49:219-237
25. Verhoeff NPLG (1993) Imaging neurotransmission and neuroreceptors: physiological and pharmacological basis. In: Costa DC, Morgan GF, Lassen NA (eds) New trends in nuclear neurology and psychiatry. Libbey, London, pp 36-95
26. 2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563